With its expertise in lipid science and the therapeutic benefits of essential fatty acids, Amarin Corporation is dedicated to enhancing cardiovascular health. Their lead candidate, AMR101, is currently undergoing pivotal Phase 3 trials to assess its efficacy in lowering triglycerides in patients with very high triglycerides and those with mixed dyslipidemia who are taking statins. Headquartered in Dublin, Ireland, with research and development based in Mystic, Connecticut, Amarin aims to commercialize and develop therapeutics, including their flagship product Vascepa, to address cardiovascular health concerns. Listed on NASDAQ as AMRN, the company strives to revolutionize cardiovascular disease treatment.